VI
NVCR icon

Versor Investments’s NovoCure NVCR Stock Holding History

Versor Investments’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,500
Closed -$195K – 875
2024
Q1 		$195K Buy
+12,500
New +$184K 0.04% 619
2023
Q2 		– Sell
-11,647
Closed -$700K – 766
2023
Q1 		$700K Buy
+11,647
New +$931K 0.09% 207
2022
Q4 		– Sell
-10,776
Closed -$819K – 894
2022
Q3 		$819K Sell
10,776
-9,755
-48% -$761K 0.05% 292
2022
Q2 		$1.43M Buy
+20,531
New +$1.55M 0.05% 157

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Versor Investments's NVCR Position: Q2 2024 in Review

Versor Investments sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 12,500 shares — an estimated $195K sold.

Versor Investments first reported a position in NVCR in Q2 2022 and held it in 4 quarters. The position peaked at $1.43M in Q2 2022. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

  • Versor Investments reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
  • Versor Investments sold 12,500 NovoCure shares in Q2 2024, an estimated $195K.
  • Versor Investments first reported a position in NovoCure in Q2 2022 and held it in 4 quarters.
  • Versor Investments's NovoCure position peaked at $1.43M in Q2 2022.
  • 236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Versor Investments's 13F filing for Q2 2024, filed 1 Aug 2024.